Emergent TAV-in-TAV for Failed Bioprosthetic Valve With Severe Aortic Regurgitation Presenting as a Myocardial Infarction Authors: Jeremy Wells, Vijay Iyer, Stanley Fernandez, Kinan Dalal, Mohamed Abdel-Aal Ahmed Published: 2026 ABSTRACT BackgroundWe present an 82-year-old man with a history of coronary artery disease status after coronary artery bypass grafting, percutaneous coronary intervention, hypertension, and severe aortic stenosis status post transcatheter aortic valve replacement who presented to the emergency department with substernal chest pain and dyspnea.Case SummaryThe patient's workup revealed ST-segment elevations in V1 and chest x-ray suggestive of pulmonary edema. He became hypotensive and was started on pressor support. Left heart catheterization showed a stable coronary artery anatomy but severe aortic regurgitation through a failing Evolut valve (Medtronic). Because of hemodynamic instability, we proceeded with an emergent transcatheter aortic valve-in-valve procedure with a new valve, which resolved his aortic regurgitation.DiscussionTranscatheter aortic valve replacement is typically performed to treat aortic stenosis or regurgitation in stable patients, but in this case it was used to mitigate a patient's severe aortic regurgitation through a prior bioprosthetic valve because of his hemodynamic instability.Take-Home MessageThis case highlights the use of an emergent transcatheter aortic valve-in-valve bioprosthetic valve replacement to treat a patient with cardiogenic shock secondary to severe aortic insufficiency. History of Presentation An 82-year-old man presented to the emergency department with crushing substernal chest pain that began several hours before arrival. He reported associated dyspnea and diaphoresis but denied dizziness, syncope, or recent drug use. Per emergency medical services, the patient was hypoxic when they arrived at his home, and he was placed on supplemental oxygen via nasal cannula and given intravenous fluids and aspirin. On physical examination, the patient appeared to be in acute distress. Cardiac examination was unremarkable with normal S1 and S2 appreciated and intact capillary refill. The patient was tachypneic with diffuse bilateral crackles on auscultation. Examination was otherwise unremarkable. Because of hypoxia to 88% on 5 L via nasal cannula, the patient was placed on a nonrebreather mask. Past Medical History The patient’s medical history was positive for coronary artery disease status after coronary artery bypass grafting (2 times), percutaneous coronary intervention, hypertension, hyperlipidemia, type 2 diabetes mellitus, and severe aortic stenosis status post transcatheter aortic valve replacement (TAVR) in 2017 with a 29-mm Evolut (Medtronic). Differential Diagnosis The differential diagnoses were acute coronary syndrome (ST-segment elevation myocardial infarction or non–ST-segment elevation myocardial infarction), aortic dissection, pulmonary embolism, esophageal spasm, flash pulmonary edema due to aortic insufficiency, and pneumonia. Investigations An electrocardiogram (ECG) performed in the emergency department revealed sinus rhythm with first-degree atrioventricular block, right bundle branch block, and ST-segment elevations in aVR and V1 with ST-segment depressions in II, III, aVF, and V3 to V6. A chest x-ray revealed cardiomegaly, low lung volumes, and moderate diffuse linear interstitial lung disease most commonly seen with linear interstitial pulmonary edema. Because of concern for acute coronary ischemia, the patient was given a 4,000-U heparin bolus and 180 mg of ticagrelor in the emergency department. Initial laboratory values were significant for a troponin of 0.03, brain natriuretic peptide of 253, and myoglobin of 130. While in the emergency department, the patient became hypotensive with a mean arterial pressure <65 and was started on pressor support with norepinephrine. Of note, the patient had an outpatient transthoracic echocardiogram less than a month before this presentation with a normal functioning TAVR valve. The interventional cardiology service was consulted. Given bibasilar crackles, hypoxia, hypotension, and acute ischemic changes on ECG, there was concern for acute myocardial infarction and cardiogenic shock. The patient was taken to the cardiac catheterization laboratory. On arrival, the patient had an episode of emesis and was emergently intubated by anesthesia to protect his airway before left heart catheterization. Coronary angiography revealed that the patient's coronary anatomy had remained stable since a prior angiogram in 2021, with a patent left internal mammary artery to left anterior descending artery and a patent left main/left circumflex artery stent. The right coronary artery was chronically occluded with left to right collaterals. An aortogram revealed severe, wide-open aortic regurgitation (Figure 1, Video 1). Transthoracic echocardiography revealed a severely abnormal left ventricular ejection fraction of 20% to 25%, normal right ventricular systolic function, mild to moderate mitral regurgitation, and a prior 29-mm Evolut TAVR valve with severe aortic insufficiency (Videos 2 and 3). Because of his hemodynamic instability and worsening hypoxia with evidence of end-organ dysfunction including renal and liver dysfunction, the decision was made to proceed with emergency valve-in-valve TAVR.Figure 1Severe Aortic Insufficiency Noted on 4-Chamber TTEDoppler transthoracic echocardiography apical 4-chamber view showing severe aortic insufficiency through the patient's prior transcatheter aortic valve replacement valve. Severe Aortic Insufficiency Noted on 4-Chamber TTE Doppler transthoracic echocardiography apical 4-chamber view showing severe aortic insufficiency through the patient's prior transcatheter aortic valve replacement valve. Management After further discussion with the on-call cardiothoracic surgeon, the patient was believed to be high-risk for redo surgery because of his advanced age, history of sternotomy twice, and pre-existing cardiogenic shock with reduced left ventricular ejection fraction and high pressor requirements. The decision was made to proceed with emergent TAVR. The previous cardiac computed tomography from 2017 was reviewed, and annular sizing was consistent with a 29-mm Evolut vs 23-mm SAPIEN valve (Edwards Lifesciences). The procedure was performed in 2024 with minimal readily available software to guide the transcatheter aortic valve-in-valve procedure. The decision was made to proceed with a 23-mm SAPIEN valve. The coronary anatomy was reviewed, and the left coronary sinus was large both on angiography and by computed tomography with minimal concern for coronary obstruction. The sinotubular junction sizing was also believed to be adequate. The right coronary artery was occluded and collateralized from the left. Access was already obtained in the right common femoral artery for angiography. Vascular access was obtained via the left common femoral artery and left common femoral vein under ultrasound and fluoroscopic guidance. Six-French long sheaths were placed in the left common femoral artery and vein. A 5-F temporary transvenous pacer was placed in the right ventricular apex, and pacing thresholds were tested and adequate. A 5-F pigtail catheter was placed in the aortic root, and the optimal angle for deployment was confirmed. The arteriotomy site was dilated with an 8-F sheath, and 2 Perclose (Abbott) closure device sutures were deployed in a preclosed fashion. A Lunderquist wire (Cook Medical) was then used to advance the 14-F Edwards TAVR sheath. The aortic valve was crossed with a 5-F pigtail catheter. A double-curve Lunderquist guidewire was then placed in the left ventricular apex via the pigtail catheter, after which the pigtail catheter was removed. A 23-mm Edwards Lifesciences SAPIEN 3 Ultra Resilia bioprosthetic valve was placed in the aortic position with rapid ventricular pacing (Video 4). The final position of the valve was appropriate with no residual aortic stenosis and no significant aortic insufficiency (Figure 2, Video 5). Aortography demonstrated adequate flow into the left coronary sinus. The wires and sheaths were removed, and the primary arteriotomy was closed after tightening the Perclose sutures and achieving hemostasis. A limited bilateral iliofemoral angiogram was performed, which confirmed hemostasis. A repeat left coronary angiography was performed with a 5-F JL3.5 catheter confirming patency of the left main coronary artery and a readily accessible left coronary artery. The patient was transferred to the cardiovascular intensive care unit in stable condition.Figure 2Resolution of Aortic Insufficiency Noted on FluorscopyIntraprocedural aortogram showing resolution of aortic insufficiency with no contrast dye present in the left ventricle after deployment of the new aortic valve. Resolution of Aortic Insufficiency Noted on Fluorscopy Intraprocedural aortogram showing resolution of aortic insufficiency with no contrast dye present in the left ventricle after deployment of the new aortic valve. Outcome and Follow-Up On arrival to the cardiac care unit, the patient remained sedated but no longer required pressors with a blood pressure of 140/78. Volume status was optimized with intravenous diuretics. Postprocedural transthoracic echocardiogram revealed moderately abnormal but improved left ventricular ejection fraction of 35% to 40%, mild left atrial enlargement, and a newly implanted valve-in-valve TAVR with normal gradients and area and no aortic insufficiency. The following day, the patient was placed on norepinephrine and milrinone because of hypotension, bumetanide because of peripheral edema and pulmonary vascular congestion on chest x-ray, and heparin per the acute coronary syndrome protocol because of concern for rising troponin levels above 100. Later that day, he underwent right heart catheterization, revealing the following measurements: central venous pressure: 23, right ventricle: 41/27, pulmonary artery: 53/38, and pulmonary capillary wedge pressure: 33. The following day his bumetanide dosage was decreased, he was weaned off propofol, and he was awake and following commands. One day later he was extubated and weaned off pressors. His pulmonary arterial pressures via his right internal jugular central line had improved to 20s/10s with continued diuresis, and his renal function was improving. He was transferred to the cardiology floor, transitioned to oral bumetanide, and placed on guideline-directed medical therapy. His discharge was delayed until 1 week later because of concern for aspiration and difficulty swallowing foods. Discussion TAVR has become an increasingly attractive option for valve replacement in patients with aortic stenosis or insufficiency, especially patients who are older or are poor surgical candidates. Although TAVR was initially reserved for patients with high surgical risk, its approval has expanded to patients at intermediate and low surgical risk. The Evolut Low-Risk trial compared TAVR with surgical aortic valve replacement and found TAVR to be noninferior with respect to death and disabling stroke at 24 months.1 Forrest et al2 examined 6-year outcomes in the Evolut Low-Risk trial and found no difference in all-cause mortality between TAVR and surgical aortic valve replacement. They did, however, find a higher reintervention rate for TAVR compared with surgery, which was driven by an increased incidence of aortic regurgitation. These authors also performed an exploratory analysis to examine associations between balloon postdilation and reintervention and found a significant association between TAVR valves that underwent off-guidance balloon postdilation compared with on-guidance balloon postdilation or no balloon postdilation.2 In our patient's case, no balloon postdilation was performed, which may have contributed to premature failure of the valve. Our patient presented with bioprosthetic valve failure from his TAVR from 7 years ago, resulting in wide-open aortic insufficiency and cardiogenic shock. Traditionally, the treatment of choice for bioprosthetic valve dysfunction has been surgical replacement.3 In decompensated patients with severe aortic insufficiency or stenosis due to valve dysfunction, surgical options are limited and carry high perioperative risk. In these instances, transcatheter intervention with a valve-in-valve procedure is a less-invasive alternative with a lower perioperative mortality; however, its long-term durability may be inferior.4 A retrospective study by Goel et al5 examined over 5,000 patients experiencing cardiogenic shock who were treated with emergent TAVR; 12% of these patients underwent valve-in-valve redo TAVR, whereas 88% had TAVR of their native valves. The outcomes were similar between both groups, with no significant difference in 1-year survival. Our patient's presentation was consistent with acutely decompensated heart failure resulting in cardiogenic shock given his dyspnea, chest pain, hypotension, ischemic changes on ECG, and pulmonary vascular congestion on imaging. Transthoracic echocardiography performed in the cardiac catheterization laboratory confirmed severe aortic insufficiency through a prior bioprosthetic valve. Given his hemodynamic instability and after discussion with cardiothoracic surgery, redo TAVR was determined to be a more favorable option compared with surgical intervention. Replacement of this patient's failing aortic bioprosthetic valve with a new valve via a transcatheter approach successfully reversed his aortic insufficiency and cardiogenic shock, leading to his eventual discharge. Conclusions Acute bioprosthetic aortic valve failure can be life-threatening and present with decompensated cardiogenic shock if severe. To remedy this, the failing valve must be replaced either surgically or through a transcatheter approach. In our patient with cardiogenic shock resulting from aortic insufficiency through a prior bioprosthetic valve, a valve-in-valve TAVR procedure successfully eliminated his aortic insufficiency and reversed his hemodynamic instability. Funding Support and Author Disclosures The authors have reported that they have no relationships relevant to the contents of this paper to disclose.Take-Home Messages•Patients who have bioprosthetic valve dysfunction typically undergo surgical replacement for equipment failure.•This case highlights the use of an emergent valve-in-valve procedure to mitigate aortic insufficiency in a hemodynamically unstable patient. Take-Home Messages •Patients who have bioprosthetic valve dysfunction typically undergo surgical replacement for equipment failure.•This case highlights the use of an emergent valve-in-valve procedure to mitigate aortic insufficiency in a hemodynamically unstable patient. •Patients who have bioprosthetic valve dysfunction typically undergo surgical replacement for equipment failure. Patients who have bioprosthetic valve dysfunction typically undergo surgical replacement for equipment failure. •This case highlights the use of an emergent valve-in-valve procedure to mitigate aortic insufficiency in a hemodynamically unstable patient. This case highlights the use of an emergent valve-in-valve procedure to mitigate aortic insufficiency in a hemodynamically unstable patient.